FDA Approves TECENTRIQ — Genentech, Inc.

# FDA Approves Genentech's TECENTRIQ (atezolizumab) for Bladder Cancer Genentech, Inc. received FDA approval for TECENTRIQ (atezolizumab), a PD-L1 inhibitor administered intravenously, positioning the company to capture market share in the immunotherapy space as the first anti-PD-L1 monoclonal antibody approved by the agency. The approval marks a significant entry point for Genentech in the fast-growing cancer immunotherapy market, which is expected to reach billions in annual sales